Business Context and Reporting Period
Company: Genworth Financial, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 30, 2013
Reporting Period: Quarter ended March 31, 2013
This filing serves as a notification that the company issued a press release and a financial supplement regarding its first-quarter 2013 results. The detailed financial data is contained in the attached exhibits (Exhibit 99.1 and 99.2) and is incorporated by reference.
Key Financial Metrics
The provided text is a cover document for the Form 8-K and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are located in the referenced exhibits (Press Release and Financial Supplement) which are not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms the issuance of results for the quarter ended March 31, 2013.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release and financial supplement containing management commentary, but the text of these documents is not present in the input.
Risks and Contingencies: No specific risks or contingencies are detailed in this cover document.
Legal Disclaimer: The company explicitly states that the information in this report is "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor subject to its liabilities. It also states the information shall not be incorporated by reference into other filings unless expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2013 revenue, net income, and earnings per share figures.
- Examine Exhibit 99.2 (Financial Supplement) for detailed liquidity, debt, and margin analysis.
- Verify the company's forward-looking guidance and outlook statements contained in the press release.
- Confirm the impact of any unusual items or contingencies disclosed in the full financial supplement.